911029-10-2

Upstream product

• 76-05-1 trifluoroacetic acid 
• 18791-75-8 4-Bromothiophen-2-aldehyde 
• 41498-07-1 4-bromo-5-nitrothiophene-2-carbaldehyde 
• 911030-40-5 5-bromo-4-[S-(3-bromophenyl)-N-tosylsulfoximino]-thiophene-2-carbonitrile 
• 911030-41-6 4-[S-(3-bromophenyl)-N-tosylsulfoximino]-5-methylsulfanyl-thiophene-2-carbonitrile 
• 19742-90-6 1-bromo-3-[(3-bromophenyl)disulfanyl]benzene 
• 6320-01-0 3-Bromothiophenol 
• 911030-36-9 4-[S-(3-bromophenyl)-sulfoximino]-5-methylsulfanyl-thiophene-2-carboximidic acid methyl ester 
• 911030-43-8 4-(3-bromo-benzenesulfoximine)-5-rnethylsulfanyl-thiophene-2-carboamide 
• 911030-39-2 5-bromo-4-(3-bromo-benzenesulfinyl)-thiophene-2-carbonitrile 
• 911030-38-1 5-bromo-4-(3-bromo-phenylsulfanyl)-thiophene-2-carbonitrile 
• 911030-37-0 5-amino-4-(3-bromo-phenylsulfanyl)-thiophene-2-carbonitrile 
• 911030-33-6 methyl 3-bromobenzenesulfinate 
• 631911-76-7 4-(3-bromo-benzenesulfinyl)-5-nitro-thiophene-2-carbonitrile 

Relevant academic research and scientific papers

NOVEL THIOPHENE SULFOXIMINES FOR TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS

Disclosed are compounds for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade. Said compounds are of Formula I I or a solvate, hydrate, pharmaceutically acceptable salt, or prodrug thereof; wherein Ra, Rb, and Rc are defined in the specification, as are A Z, Q, R1 and R2.